Chronic neonatal lung disease (CNLD) following premature birth continues to occur in a significant number of infants1. Improved modern neonatal care has significantly increased survival and decreased the majority of significant complications following preterm birth. While neurological, gastrointestinal, and ophthalmological complications have decreased, respiratory complications remain largely unchanged over the past 2 decades with nearly one in two infants born before 28-week gestation developing lung disease.
Prematurity, inflammation, oxidative damage, and ventilator-associated injury all play a role in the pathophysiology of CNLD and poor respiratory outcomes following preterm birth2,3,4. Despite the significant advancements of modern neonatal care, limited effective therapy is available to treat or prevent the development of CNLD5,6.
New approaches and interventions are required to develop therapy to prevent and treat CNLD. Intrapulmonary drug delivery is an attractive intervention to deliver drugs to the lung and could alter the course of respiratory disease in neonates. Intrapulmonary drug therapy has the benefit of direct delivery of active agents to the lung, thereby minimizing accumulation of the drug in off-target organs7,8, potentially limiting systemic side effects. Despite over 2 decades of intrapulmonary surfactant replacement, no additional intrapulmonary drugs have been validated to improve neonatal respiratory outcomes. Recently, budesonide-surfactant combination therapy has been described to improve pulmonary outcomes following preterm birth in mechanically ventilated infants9,10. However, much remains unknown on the functional and structural effects of IT drug therapy, few new therapies have been identified, and the value of intratracheal drug delivery in the neonatal period remains uncertain. Animal models are required to identify potential drugs and aid the development of much needed therapy for CNLD.
Animal studies examining newborn lung disease are most commonly performed in small animal models such as rats and mice11,12,13. The rabbit has the additional advantage of preterm delivery to more closely mimic the structure and function of the immature human lung14. A limitation of the preterm rabbit is the difficulty of accessing the airway to allow the delivery of intrapulmonary interventions. While adult rabbit and rodent models allow trans-oral endotracheal intubation, these techniques are difficult in newborn pups due to their small size and the unique anatomy of the upper airway15,16. Alternative approaches are required to allow access to the trachea for the delivery of drugs in newborn rabbit pups.
In this manuscript, we describe the use of a transcutaneous needle tracheostomy to allow tracheal intubation and drug delivery.